靶向宿主固有免疫和适应性免疫以实现慢性乙型肝炎的功能性治愈
Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B.
作者信息
Ezzikouri Sayeh, Kayesh Mohammad Enamul Hoque, Benjelloun Soumaya, Kohara Michinori, Tsukiyama-Kohara Kyoko
机构信息
Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca 20250, Morocco.
Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan.
出版信息
Vaccines (Basel). 2020 May 11;8(2):216. doi: 10.3390/vaccines8020216.
Despite the availability of an effective preventive vaccine for hepatitis B virus (HBV) for over 38 years, chronic HBV (CHB) infection remains a global health burden with around 257 million patients. The ideal treatment goal for CHB infection would be to achieve complete cure; however, current therapies such as peg-interferon and nucleos(t)ide analogs are unable to achieve the functional cure, the newly set target for HBV chronic infection. Considering the fact functional cure has been accepted as an endpoint in the treatment of chronic hepatitis B by scientific committee, the development of alternative therapeutic strategies is urgently needed to functionally cure CHB infection. A promising target for future therapeutic strategies is immune modulation to restore dysfunctional HBV-specific immunity. In this review, we provide an overview of the progress in alternative therapeutic strategies, including immune-based therapeutic approaches that enhance host innate and adaptive immunity to achieve and increase the functional cure from CHB infection.
尽管有效的乙型肝炎病毒（HBV）预防性疫苗已问世38年有余，但慢性HBV（CHB）感染仍是一项全球性的健康负担，患者约达2.57亿。CHB感染的理想治疗目标是实现完全治愈；然而，目前的疗法，如聚乙二醇干扰素和核苷（酸）类似物，无法实现功能性治愈，这是HBV慢性感染新设定的目标。鉴于功能性治愈已被科学委员会认可为慢性乙型肝炎治疗的终点，迫切需要开发替代治疗策略以实现CHB感染的功能性治愈。未来治疗策略的一个有前景的靶点是免疫调节，以恢复功能失调的HBV特异性免疫。在本综述中，我们概述了替代治疗策略的进展，包括基于免疫的治疗方法，这些方法可增强宿主的固有免疫和适应性免疫，以实现并提高CHB感染的功能性治愈率。
Zotero 插件